Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.
Laura RozenblumCaroline HouillierAmandine BaptisteCarole SoussainVéronique EdelinePhilippe NaggaraMarine SoretValérie Causse-LemercierLise WillemsSylvain ChoquetRenata UrsuDamien GalanaudLisa BelinKhê Hoang-XuanAurélie KasPublished in: Neuro-oncology (2024)
LOCALYZE, NCT03582254, ancillary of phase III clinical trial BLOCAGE01, NCT02313389 (Registered July 10, 2018-retrospectively registered) https://clinicaltrials.gov/ct2/show/NCT03582254?term=LOCALYZE&draw=2&rank=1.
Keyphrases
- phase iii
- clinical trial
- positron emission tomography
- open label
- computed tomography
- pet ct
- phase ii
- double blind
- pet imaging
- preterm infants
- placebo controlled
- diffuse large b cell lymphoma
- magnetic resonance imaging
- image quality
- dual energy
- contrast enhanced
- cerebrospinal fluid
- magnetic resonance
- study protocol
- preterm birth